190 likes | 341 Vues
Cytomegalovirus promotes expansion of pre-existing T-cell immunity following allogeneic transplantation significantly modulating chimerism status.
E N D
Cytomegalovirus promotes expansion of pre-existing T-cell immunity following allogeneic transplantation significantly modulating chimerism status Rob S. Sellar, Frederick Arce Vargas, Jake Y. Henry, Stephanie Verfuerth, Sarah Charrot, Sergio A. Quezada, Stephen Mackinnon, Kirsty J. Thomson, and Karl S. Peggs* University College London Cancer Institute
The Dogma • CMV reactivations are increased if you T-deplete • Highest risk population R+/D- • New therapeutic strategies are needed
What if it is wrong? CMV reactivations
What if it is wrong? CMV reactivations Days of treatment
Problematic CMV reactivations are associated with low levels of recipient chimerism CMV reactivations
Problematic CMV reactivations are associated with low levels of recipient chimerism CMV reactivations Days of treatment
Problematic CMV reactivations are restricted to patients with significant GvHD CMV reactivations
Problematic CMV reactivations are restricted to patients with significant GvHD Days of treatment CMV reactivations
Patients with significant GvHD had lower absolute lymphocyte counts
Streptamer positive cells are exclusively of recipient origin
Streptamer positive cells are exclusively of recipient origin Donor Recipient CD4+ CD8+ Strep- CD8+ Strep+ Patient 1 Patient 2 Patient 3
DLI can be followed by a primary immune response to CMV Donor Recipient CD8+ Strep- CD8+ Strep+ CD4+ Pre-DLI 4 weeks 8 weeks 12 weeks 18 weeks
Conclusions • recipient-derived virus-specific T cells that have escaped deletion during non-myeloablative conditioning can protect against recurrent CMV infection • expansion of these cells post transplant has a significant influence on levels of recipient chimerism • “Campath Paradox” - T cell-depletion in the R+D- setting may paradoxically foster more rapid reconstitution of protective antiviral immunity by reducing graft-versus-host directed alloreactivity and the associated elimination of the recipient T cell compartment
Acknowledgements • UCL Cancer Institute • Tumour Immunogy Group – Dr Karl S Peggs – Dr Sergio A Quesada – Dr Frederick Arce Vargas – Jake Y Henry • Royal Free Hospital – Professor Stephen Mackinnon – Stephanie Verfuerth • UCLH – Dr Kirsty Thomson – Dr Sarah Charrot